Research Brief
Semaglutide: Research Overview
An approved GLP-1 receptor agonist (Ozempic / Wegovy / Rybelsus) for type 2 diabetes and weight management — supplied here as research-grade material for laboratory use only, not the approved medicine.
Last reviewed: June 2, 2026
For Laboratory Research Use Only
Content on this page describes published research findings. LUMEN BASED does not make therapeutic claims. Consult the primary literature and your institutional review board for protocol design. These products are not for human consumption.
What is Semaglutide?
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist. Unlike the research peptides elsewhere in this library, semaglutide is an approved prescription medicine — first approved in 2017–2018, marketed as Ozempic (type 2 diabetes), Wegovy (chronic weight management), and Rybelsus (oral). It lowers blood glucose by stimulating insulin secretion and reduces body weight. [Dhillon 2018]
What the published clinical research found
Semaglutide has one of the largest randomized-trial evidence bases of any compound on this site.
Type 2 diabetes (SUSTAIN 1)
In a phase-3 trial of 387 treatment-naïve patients, once-weekly semaglutide reduced HbA1c by about 1.45–1.55% (versus about 0.02% with placebo) and body weight by about 3.7–4.5 kg (versus about 1.0 kg); gastrointestinal effects (nausea, diarrhea) were most common. [Sorli 2017]
Weight management (STEP 1)
In 1,961 non-diabetic adults, semaglutide 2.4 mg weekly produced a mean 14.9% weight reduction versus 2.4% with placebo over 68 weeks; about 86% achieved at least 5% weight loss, versus about 32% with placebo. [Wilding 2021]
Cardiovascular outcomes (SELECT)
In 17,604 patients with established cardiovascular disease and overweight/obesity (without diabetes), semaglutide reduced the composite of cardiovascular death, myocardial infarction, or stroke to 6.5% versus 8.0% with placebo (hazard ratio 0.80) over roughly 40 months — though discontinuations for adverse events were higher (16.6% versus 8.2%). [Lincoff 2023]
Formulations & safety
Both subcutaneous and oral formulations lower HbA1c and body weight without increased hypoglycemia risk [Meier 2021]; safety reviews of the trial programs report mostly transient, mild-to-moderate gastrointestinal effects and an increased risk of biliary disease, with no unexpected severe safety signals. [Smits 2021]
Regulatory status & research-use only
Semaglutide is an approved prescription medication available only through licensed healthcare providers (Ozempic, Wegovy, Rybelsus). LUMEN BASED supplies semaglutide strictly as a research-grade material for laboratory use only. It is not the approved pharmaceutical product, is not intended for human or veterinary use, and nothing on this page is medical advice, a prescription, or a recommendation to use it. Anyone considering treatment should consult a licensed physician. Every reference below links to its primary source on PubMed for independent verification.
Verify the batch you're studying
Each Semaglutide lot ships with a third-party Certificate of Analysis (HPLC, mass spectrometry, identity confirmation). Pair the batch in your study with the matching COA before publishing or reporting results.
View COA for Semaglutide →References
- Dhillon S (2018). Semaglutide: First Global Approval. PubMed
- Sorli C et al. (2017). Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). PubMed
- Wilding JPH et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). PubMed
- Lincoff AM et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). PubMed
- Smits MM et al. (2021). Safety of Semaglutide. PubMed
- Meier JJ (2021). Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation. PubMed
For Research Use Only. All LUMEN BASED compounds are strictly for in vitro laboratory research by qualified researchers. Not for human or animal consumption. Not approved by the FDA for therapeutic use.